Annexon Bioscience is a clinical-stage biopharmaceutical company focused on developing therapies for autoimmune and neurodegenerative diseases. They make money by advancing their pipeline of drug candidates through clinical trials and partnering with larger pharmaceutical companies for development and commercialization. Founded in 2011, Annexon is notable for its pioneering work on complement pathway inhibition, which aims to halt disease progression by targeting the immune system's complement system.